Claims for Patent: 9,579,350

Summary for Patent: 9,579,350

Title:	Human amniotic fluid preparation having long-term stability
Abstract:	Methods of preparing sterile de-cellularized human amniotic fluid that is amenable for long-term storage without loss of biological functions have been developed. In particular, the methods involve refrigeration steps to maximize shelf-life while retaining most of the important growth factors and other molecules present in the fresh amniotic fluid for effective therapeutic application. Use of the compositions is intended for therapeutic purposes and will alleviate pain or discomfort associated with any disorders or diseases, particularly those involving eyes and joints, or fibrotic disorders such as COPD.
Inventor(s):	Harrell; Carl Randall (Tarpon Springs, FL)
Assignee:	MAM Holdings of West Florida, L.L.C. (Tarpon Springs, FL)
Application Number:	15/053,497
Patent Claims:	1. A method for preparing a composition of sterile, de-cellularized human amniotic fluid (D-HAF) comprising: (a) collecting amniotic fluid under sterile conditions from a subject to produce a sample of raw amniotic fluid; (b) de-cellularizing the raw amniotic fluid to remove only cells and/or particulate matter by a series of centrifugation and filtration steps to produce a de-cellularized amniotic fluid, wherein the quantity of the proteins in the de-cellularized amniotic fluid is between 50% to 100% of the raw amniotic fluid; and (c) placing the de-cellularized amniotic fluid in a sterile vessel at a temperature from about 1.degree. C. to about 20.degree. C. for one or more days, weeks, months, or up to a year, or more than a year, wherein the de-cellularized amniotic fluid is not concentrated, diluted, fractionated, heat- or alcohol-treated relative to the raw fluid. 2. The method of claim 1, wherein the method for preparing further comprising incubating the de-cellularized amniotic fluid at a temperature from about 1.degree. C. to about 20.degree. C. for a period of time effective to reduce the quantity of one or more inflammatory factors relative to the raw amniotic fluid. 3. The method of claim 1, wherein the temperature is from about 2.degree. C. to about 8.degree. C. 4. The method of claim 3, wherein the temperature is about 4.degree. C. 5. The method of claim 1, wherein the amniotic fluid further comprises one or more preservatives. 6. The method of claim 1, wherein the de-cellularized amniotic fluid retains more than 80% of the amniotic proteins compared to the raw amniotic fluid. 7. The method of claim 2, wherein the one or more inflammatory molecules are selected from the group consisting of Eotaxin-2, IL-6, PARC/CCL18, total GRO, ENA-78/CXCL-5, 6Ckine and MIP-3.alpha.. 8. A composition of de-cellularized amniotic fluid prepared according to claim 1. 9. The composition of claim 8 formulated for administration to the eye. 10. The composition of claim 8 formulated for injection into a joint. 11. The composition of claim 8 diluted with sterile water, saline or buffer. 12. The composition of claim 8 formulated into a gel, cream or ointment. 13. The composition of claim 8 packaged into a sterile dropper bottle for administration of drops into an eye for at least 30 days. 14. The composition of claim 8 mixed with nebulizing solution for administration using an aerosol or nebulizer. 15. The composition of claim 8 lyophilized into a bottle for resuspension with sterile water, saline or buffer suitable for injection. 16. The composition of claim 8 formulated with liposomes, polymeric particles or a polymeric implant. 17. The composition of claim 8 further comprising at least one additional therapeutic, prophylactic or diagnostic agent. 18. A method of treating at least one symptom of a disease or disorder comprising administering an effective amount of the composition of claim 1. 19. The method of claim 18 wherein the composition is applied to or into an eye. 20. The method of claim 18 wherein the composition is injected into or adjacent a joint, ligament, or tendon, or prosthetic. 21. The method of claim 18 wherein the composition is administered to the pulmonary or nasal system. 22. The method of claim 18 wherein the composition is injected into tissue at a site of wrinkles or aged skin.

Details for Patent 9,579,350

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-22